Dimensional Fund Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $124M | Buy |
732,877
+21,115
| +3% | +$3.13M | 0.02% | 1023 |
|
|
2026
Q1 | $93.8M | Sell |
711,762
-4,713
| -0.7% | -$625K | 0.02% | 1101 |
|
|
2025
Q4 | $102M | Buy |
716,475
+6,353
| +0.9% | +$920K | 0.02% | 1063 |
|
|
2025
Q3 | $99.7M | Buy |
710,122
+25,683
| +4% | +$3.48M | 0.02% | 1064 |
|
|
2025
Q2 | $86M | Buy |
684,439
+68,803
| +11% | +$7.89M | 0.02% | 1139 |
|
|
2025
Q1 | $68.1M | Buy |
615,636
+65,479
| +12% | +$8.29M | 0.02% | 1270 |
|
|
2024
Q4 | $75.1M | Buy |
550,157
+26,525
| +5% | +$3.28M | 0.02% | 1258 |
|
|
2024
Q3 | $60.3M | Buy |
523,632
+50,703
| +11% | +$6.95M | 0.01% | 1396 |
|
|
2024
Q2 | $65.1M | Buy |
472,929
+147,907
| +46% | +$20.3M | 0.02% | 1282 |
|
|
2024
Q1 | $44.8M | Sell |
325,022
-11,514
| -3% | -$1.57M | 0.01% | 1532 |
|
|
2023
Q4 | $44.3M | Buy |
336,536
+5,907
| +2% | +$680K | 0.01% | 1529 |
|
|
2023
Q3 | $37.2M | Sell |
330,629
-5,535
| -2% | -$583K | 0.01% | 1535 |
|
|
2023
Q2 | $31.7M | Buy |
336,164
+15,682
| +5% | +$1.53M | 0.01% | 1678 |
|
|
2023
Q1 | $32.4M | Buy |
+320,482
| New | +$33.3M | 0.01% | 1641 |
|
|
2022
Q3 | $38M | Buy |
357,539
+2,474
| +0.7% | +$251K | 0.01% | 1435 |
|
|
2022
Q2 | $34.6M | Sell |
355,065
-62,539
| -15% | -$5.77M | 0.01% | 1560 |
|
|
2022
Q1 | $39.1M | Buy |
417,604
+117,422
| +39% | +$9.95M | 0.01% | 1586 |
|
|
2021
Q4 | $25.6M | Buy |
300,182
+12,225
| +4% | +$1.12M | 0.01% | 1858 |
|
|
2021
Q3 | $27.6M | Buy |
287,957
+16,925
| +6% | +$1.6M | 0.01% | 1831 |
|
|
2021
Q2 | $26.4M | Buy |
271,032
+14,090
| +5% | +$1.35M | 0.01% | 1916 |
|
|
2021
Q1 | $25M | Buy |
256,942
+2,761
| +1% | +$290K | 0.01% | 1929 |
|
|
2020
Q4 | $24.4M | Buy |
254,181
+11,612
| +5% | +$1.12M | 0.01% | 1879 |
|
|
2020
Q3 | $23.3M | Buy |
242,569
+65,787
| +37% | +$7.61M | 0.01% | 1761 |
|
|
2020
Q2 | $21.6M | Buy |
176,782
+12,752
| +8% | +$1.41M | 0.01% | 1832 |
|
|
2020
Q1 | $14.2M | Sell |
164,030
-11,848
| -7% | -$1.16M | 0.01% | 1937 |
|
|
2019
Q4 | $18.9M | Sell |
175,878
-4,315
| -2% | -$452K | 0.01% | 2073 |
|
|
2019
Q3 | $16.2M | Sell |
180,193
-1,375
| -0.8% | -$128K | 0.01% | 2122 |
|
|
2019
Q2 | $15.3M | Buy |
181,568
+10,257
| +6% | +$842K | 0.01% | 2203 |
|
|
2019
Q1 | $15.1M | Sell |
171,311
-1,946
| -1% | -$163K | 0.01% | 2209 |
|
|
2018
Q4 | $12.4M | Buy |
173,257
+6,149
| +4% | +$589K | 0.01% | 2235 |
|
|
2018
Q3 | $20.5M | Sell |
167,108
-19,904
| -11% | -$2.26M | 0.01% | 2100 |
|
|
2018
Q2 | $18.4M | Sell |
187,012
-5,252
| -3% | -$470K | 0.01% | 2143 |
|
|
2018
Q1 | $15.9M | Buy |
192,264
+270
| +0.1% | +$22.8K | 0.01% | 2175 |
|
|
2017
Q4 | $14.9M | Buy |
191,994
+10,243
| +6% | +$699K | 0.01% | 2207 |
|
|
2017
Q3 | $11.1M | Buy |
181,751
+5,554
| +3% | +$293K | ﹤0.01% | 2333 |
|
|
2017
Q2 | $8.11M | Buy |
176,197
+10,782
| +7% | +$523K | ﹤0.01% | 2440 |
|
|
2017
Q1 | $7.16M | Sell |
165,415
-538
| -0.3% | -$23.1K | ﹤0.01% | 2452 |
|
|
2016
Q4 | $6.42M | Buy |
165,953
+4,428
| +3% | +$200K | ﹤0.01% | 2477 |
|
|
2016
Q3 | $8.18M | Buy |
161,525
+18,093
| +13% | +$901K | ﹤0.01% | 2328 |
|
|
2016
Q2 | $6.52M | Buy |
143,432
+10,901
| +8% | +$502K | ﹤0.01% | 2402 |
|
|
2016
Q1 | $5.24M | Sell |
132,531
-1,772
| -1% | -$70.3K | ﹤0.01% | 2480 |
|
|
2015
Q4 | $7.6M | Buy |
134,303
+9,793
| +8% | +$498K | ﹤0.01% | 2340 |
|
|
2015
Q3 | $4.95M | Buy |
124,510
+11,938
| +11% | +$577K | ﹤0.01% | 2523 |
|
|
2015
Q2 | $5.38M | Buy |
112,572
+48,472
| +76% | +$2.06M | ﹤0.01% | 2560 |
|
|
2015
Q1 | $2.55M | Buy |
+64,100
| New | +$2.29M | ﹤0.01% | 2766 |
|
|
2013
Q3 | – | Sell |
-34,877
| Closed | -$467K | – | 3582 |
|
|
2013
Q2 | $467K | Buy |
+34,877
| New | +$428K | ﹤0.01% | 3194 |
|
Other funds holding NBIX
Dimensional Fund Advisors's NBIX Position: Q2 2026 in Review
Dimensional Fund Advisors increased its Neurocrine Biosciences (NBIX) stake by 3% in Q2 2026, buying an estimated $3.13M and bringing the position to 732,877 shares worth $124M. The position accounts for 0.02% of the portfolio, ranked #1023.
Dimensional Fund Advisors first reported a position in NBIX in Q2 2013 and has held it in 46 quarters since. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Dimensional Fund Advisors held 732,877 shares of Neurocrine Biosciences worth $124M as of Q2 2026.
- Dimensional Fund Advisors bought 21,115 Neurocrine Biosciences shares in Q2 2026, an estimated $3.13M.
- Neurocrine Biosciences made up 0.02% of Dimensional Fund Advisors's portfolio in Q2 2026, its #1023 holding.
- Dimensional Fund Advisors first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 46 quarters since.
- 778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.